Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
Cancer Immunol Immunother. 2023 Jul;72(7):2513-2514.
doi: 10.1007/s00262-023-03457-9.
1 Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
2 Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.
3 Division of Clinical Pharmacology, Department of Medicine IV; Member of the German Center for Lung Research (DZL), University Hospital, LMU, Munich, Germany.
4 German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
5 Experimental Leukemia and Lymphoma Research (ELLF), Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
6 Cancer-and Immunometabolism Research Group, LMU Gene Center, Munich, Germany.
7 AMGEN Research Munich GmbH, Munich, Germany.
8 AMGEN Inc., Thousand Oaks, CA, USA.
9 Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
10 Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. Marion.Subklewe@med.uni-muenchen.de.
11 Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. Marion.Subklewe@med.uni-muenchen.de.
12 German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany. Marion.Subklewe@med.uni-muenchen.de.